Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9262MR)

This product GTTS-WQ9262MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9262MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15026MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ11666MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ8004MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ5853MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5533MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ14792MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ5824MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ15573MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW